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Background: The aim of this study was to evaluate characteristics and risk of diabetic complications according to age at diagnosis 
among young adults with type 1 diabetes mellitus (T1DM).
Methods: A total of 255 T1DM patients aged less than 40 years were included. Patients were categorized into three groups (<20, 
20 to 29, and 30 to 40 years) according to age at diagnosis. Diabetic nephropathy (DN) was defined when spot urine-albumin cre-
atinine ratio was 300 mg/g or more and/or estimated glomerular filtration ratio (eGFR) level was 60 mL/min/1.73 m2 or less.
Results: Median age at diagnosis was 25 years and disease duration was 14 years. Individuals diagnosed with T1DM at child-
hood/adolescent (age <20 years) had lower stimulated C-peptide levels. They received more intensive insulin treatment with 
higher total daily insulin doses compared to older onset groups. The prevalence of DN was higher in the childhood/adolescent-
onset group than in older onset groups (25.3% vs. 15.3% vs. 9.6%, P=0.022). The eGFR was inversely associated with disease du-
ration whilst the degree of decrease was more prominent in the childhood/adolescent-onset group than in the later onset group 
(aged 30 to 40 years; P<0.001). Childhood/adolescent-onset group was independently associated with the risk of DN compared 
to the older onset group (aged 30 to 40 years; odds ratio, 3.47; 95% confidence interval, 1.45 to 8.33; P=0.005). 
Conclusion: In individuals with childhood/adolescent-onset T1DM, the reduction in renal function is more prominent with dis-
ease duration. Early age-onset T1DM is an independent risk of DN.
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INTRODUCTION
Despite recent novel insulin preparation and advanced tech-
nology (e.g., continuous subcutaneous insulin injection with 
continuous glucose monitoring) [1], diabetes mellitus includ-
ing type 1 diabetes mellitus (T1DM) is still associated with 
higher risk of cardiovascular disease (CVD) and overall pre-
mature mortality [2,3]. In addition, patients with T1DM have 
higher risk for end-stage renal disease (ESRD) from chronic 
kidney disease (CKD) than those with type 2 diabetes mellitus 
(T2DM) [4], and CKD in patients with T1DM is strongly re-
lated to CVD [5,6]. Macroalbuminuria which is strongly asso-
ciated with progressive loss of GFR has been traditionally used 
to define diabetic nephropathy (DN) [7]. Meanwhile, in-
creased albuminuria is known to be an independent predictor 
of prognosis in heart failure [8]. Baseline albuminuria state has 
a strong predictive role in the pathogenesis of coronary heart 
disease in patients with T1DM [9]. In the Diabetes Control 
and Complications Trial (DCCT) with Epidemiology of Dia-
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ficial effect of intensive insulin treatment on lowering CVD 
event rates by improving glycemic control is substantially at-
tenuated after adjusting for the presence of microalbuminuria 
(from P<0.001 to P=0.04) [10]. In addition, additional clinical 
parameters such as white blood cell counts, albuminuria, and 
duration of diabetes could improve the predictive power of 
cardiovascular risk in patients with T1DM [11].
Age at the diagnosis of T1DM is an important clinical pa-
rameter that defines pathophysiology, disease courses, and 
several cardiometabolic risk factors of diabetes due to various 
severity of immune and metabolic dysfunction [12]. Com-
pared to childhood-onset T1DM, the rate and pattern of β-cell 
destruction during the course of T1DM can vary according to 
genetic load [13] and the presence of pancreatic β-cell auto-
antibodies or its titers in adult-onset T1DM [14]. Although the 
incidence of typical T1DM was the highest in teenagers, more 
than half of incident T1DM Korean patients were 30 years or 
older [15]. Previous studies have shown better renal outcomes 
[16] or overall mortality [17] if T1DM is diagnosed before pu-
berty in Western countries. However, the impact of age at diag-
nosis of T1DM on complications and its potential role in strati-
fying the risk have not clearly been defined yet between those 
who is diagnosed at childhood/adolescent (aged <20 years) 
and at early adult period (aged 20 to 40 years). In addition, few 
studies have evaluated clinical characteristics and diabetic 
complications according to age at diagnosis among young 
Asian patients with T1DM. Thus, the aim of this study was to 
evaluate whether childhood/adolescent-onset T1DM had dif-
ferent clinical characteristics compared to early adult-onset 
T1DM and whether age at diagnosis was associated with the 
risk of diabetic microvascular complications in young patients 
with T1DM.
METHODS
Study design and population
The study design of the original clinical trial has been described 
elsewhere [18]. Briefly, the original study was a multi-center, 
prospective cohort study that included patients with T1DM 
who participated in the Korea National Health Insurance Ser-
vice (KNHIS) program for reimbursement of glucometer test 
strips between January 2011 and March 2015. Eligibility in-
cluded mandatory insulin treatment and those met at least one 
of the following criteria: (1) fasting C-peptide <0.6 ng/mL; (2) 
glucagon or meal stimulated C-peptide <1.8 ng/mL; (3) posi-
tive for glutamic-acid-decarboxylase and/or other autoanti-
bodies; (4) 24-hour urine C-peptide <30 μg/day; or (5) a his-
tory of diabetic ketoacidosis. In the original study design, clini-
cal and biochemical factors were collected at baseline and 
changes in the practice of self-monitoring of blood glucose, ex-
periences of severe hypoglycemia, and glycemic control state 
were compared after 1-year of follow-up. Among patients who 
participated in the study, we further retrospectively searched 
medical charts to identify the presence of diabetic microvascu-
lar complications from three hospitals (Samsung Medical Cen-
ter, Asan Medical Center, and Severance Hospital) in the cur-
rent study. We also reviewed detailed anthropometric, bio-
chemical, and clinical data as well as treatment history using 
medical charts. Among 550 patients, we limited our analyses 
to young T1DM patients who developed diabetes before 40 
years of age (n=421), excluding those who had atypical diabe-
tes (e.g., latent autoimmune diabetes in adults) or long-stand-
ing T2DM. Patients (n=166) who had no clinical data about 
diabetic microvascular complications outcomes (urine albu-
min/creatinine ratio [uACR], estimated glomerular filtration 
ratio [eGFR], and the presence of diabetic retinopathy [DR]) 
were also excluded from the analysis. Creatinine clearance was 
calculated by the Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI) equation (normal range, 90 mL/min/ 
1.73 m2 or higher) [19]. Finally, a total of 255 patients were in-
cluded in the current study and classified into three groups ac-
cording to age at diagnosis: less than age 20, aged between 20 
and 29, aged between 30 and 40. This study was approved by 
the Institutional Review Board of Samsung Medical Center 
(IRB no. 2018-07-015-001). Written informed consent by the 
patients was waived due to a retrospective nature of our study.
Definition of diabetic microvascular complications
The presence of diabetic microvascular complications was as-
sessed from medical charts review. Subject were considered to 
have DR if they had a history of mild non-proliferative reti-
nopathy or greater as diagnosed by ophthalmologists. The 
presence of DN was defined when uACR was 300 mg/g or 
more and/or eGFR level was less than 60 mL/min/1.73 m2. The 
presence or severity of diabetic neuropathy was not assessed in 
this study.
Anthropometric and biochemical measurements
Data of the following parameters were collected: age, gender, 
weight, height, body mass index (BMI), age at diagnosis, dis-
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ease duration, intensity of insulin treatment, total daily insulin 
doses (IU/kg), fasting plasma glucose, glycosylated hemoglo-
bin (HbA1c), systolic blood pressure (SBP), diastolic blood 
pressure, lipid profile, blood urea nitrogen, creatinine, uACR, 
eGFR, fasting C-peptide with stimulated C-peptide, smoking 
history, and the presence of pancreatic autoantibodies at the 
time of enrollment. The intensity of insulin treatment was di-
vided into two subgroups: (1) multiple daily injection or con-
tinuous subcutaneous insulin infusion as intensive treatment, 
and (2) premixed insulin or neutral protamine Hagedorn insu-
lin as conventional treatment. Patients who were prescribed 
any type of oral anti-diabetic drug were defined as taking oral 
agents. Fasting C-peptide levels were calculated after an over-
night fasting (n=135) and stimulated C-peptide levels were as-
sessed by performing either a 1 mg glucagon stimulation test 
(Samsung Medical Center, Asan Hospital) or a mixed meal test 
(Severance Hospital) (n=134) [20].
Statistical analysis
Data are expressed as median with interquartile ranges for 
non-evenly distributed variables. Statistical differences be-
tween groups for continuous variables were compared with 
Mann-Whitney U test or Fisher’s exact probability test for cat-
egorical variables. Analysis of variance (ANOVA) with Tukey’s 
test for multiple comparison was conducted to compare eGFR 
values and trends according to disease duration among the 
three age groups. Multivariate binary logistic regression analy-
sis with forward selection was performed to identify indepen-
dent factors associated with the risk of diabetic microvascular 
complications. In all models, we adjusted for age at diagnosis, 
duration of diabetes, HbA1c, SBP, BMI, and intensity of insulin 
treatment. Furthermore, Hosmer-Lemeshow test was per-
formed to evaluate the goodness of fit of the logistic regression 
model. All statistical analyses were performed using SPSS ver-
sion 24.0 (IBM Co., Armonk, NY, USA) and all statistical tests 
were two-tailed and the significance level was set at P<0.05. 
 
RESULTS
Characteristics of study population
Of a total of 255 patients, the median age at diagnosis was 25 
years old and the median disease duration was 14 years. Based 
on age at diagnosis, patients diagnosed at childhood/adoles-
cent (aged <20 years; n=87) had longer median disease dura-
tion (16 years vs. 13 years vs. 11 years, P=0.001), lower stimu-
lated C-peptide levels (median 0.02 ng/mL vs. 0.19 ng/mL vs. 
0.27 ng/mL, P=0.047), lower BMI (21.4 kg/m2 vs. 21.9 kg/m2 
vs. 22.4 kg/m2, P=0.002), and lower systolic blood pressure 
(median 115 mm Hg vs. 118 mm Hg vs. 121 mm Hg, P=0.022) 
compared to those diagnosed at older age group (20 to 29 and 
30 to 40 years). However, there was no significant difference in 
the proportion of the use of oral anti-diabetic drugs (P=0.065), 
antihypertensive drugs (P=0.294), or statins usage (P=0.661) 
between three groups. Among those who took anti-diabetic 
drugs (n=60), two classes of drugs were used in this study 
population: metformin (48 patients, 80%) and thiazolidinedi-
one (12 patients, 20%). Meanwhile, the younger age-onset 
group had higher proportion of intensive insulin treatment 
(81.6% vs. 60.0% vs. 57.8%, P=0.001) and higher total daily in-
sulin doses per body weight (median 0.7 IU/kg vs. 0.6 IU/kg 
vs. 0.6 IU/kg, P=0.001). Patients diagnosed at childhood/ado-
lescent had lower proportions of current/ex-smoking history 
than later onset groups (P=0.008).
Different patterns of the progression of CKD and 
albuminuria according to age at diagnosis
Regarding DN components, 33 (12.2%) patients had macroal-
buminuria (uACR ≥300 mg/g) and 24 patients (9.4%) had 
CKD (eGFR <60 mL/min/1.73 m2). The eGFR was inversely 
associated with the duration of diabetes and the degree of de-
crease was more prominent in patients diagnosed at child-
hood/adolescent (unstandardized coefficient [B] with standard 
error, –2.13±0.38; aged <20 years) than those with later onset 
Fig. 1. Relation between disease duration and estimated glo-
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(–0.88±0.30; aged 30 to 40 years; P=0.028) (Fig. 1). Mean-
while, the trend of increasing log-transformed uACR accord-
ing to disease duration was comparable among age groups 
(P=0.703) (Fig. 2). 
Risk factors of diabetic microvascular complications in 
patients with T1DM
The prevalence of DR was different among the three groups 
(<20, 20 to 29, and 30 to 40 years: 61.9% vs. 28.9% vs. 40.2%, 
P<0.001). DN was significantly more common in patients di-
agnosed at younger age (25.3% vs. 15.3% vs. 9.6%, P=0.022) 
(Table 1). With regard to risk factors associated with diabetic 
microvascular complications, longer disease duration (odds 
ratio [OR], 1.08; 95% confidence interval [CI], 1.03 to 1.12; 
P<0.001), higher HbA1c (OR, 1.36; 95% CI, 1.13 to 1.64; 
P=0.001), and youngest age group (<18 years old; OR, 3.47; 
95% CI, 1.45 to 8.33; P=0.005) were independently associated 
with the risk of DN. Meanwhile, female sex (OR, 1.89; 95% CI, 
1.16 to 3.13; P=0.011), longer disease duration (OR, 1.11; 95% 
CI, 1.08 to 1.14; P<0.001), higher HbA1c (OR, 1.28; 95% CI, 
1.12 to 1.47; P<0.001), and higher SBP (OR, 1.02; 95% CI, 1.00 
to 1.04; P=0.022) were associated with DR (Table 2). When we 
separate the outcome of DN based on the presence of macroal-
buminuria and CKD, age at diagnosis was associated with 
macroalbuminuria (OR, 6.43; 95% CI, 2.30 to 17.99; P<0.001), 




Patients who were diagnosed with T1DM at childhood/adoles-
cent (age <20 years old) took more intensive insulin treatment 
and required higher doses of daily insulin per body weight 
than those diagnosed at older ages (aged 20 to 40 years old). 
The decrease in renal function with the duration of diabetes 
was more pronounced in this youngest group (<20 years old) 
than those with later onset (30 to 40 years). The group with 
youngest age at diagnosis (<20 years old) was independently 
associated with the risk of DN, especially macroalbuminuria 
compared to the oldest age group (30 to 40 years old).
Higher levels of albuminuria were observed in patients diag-
nosed at childhood/adolescent (<20 years) regardless of the 
duration of diabetes. The magnitude of renal impairments as-
sociated with longer disease duration was more prominent in 
patients diagnosed at childhood/adolescence than those with 
later onset in this study. In addition, the youngest age-onset 
group was independently associated with higher risk of DN. In 
patients with T1DM, faster decline in residual β-cell function 
(represented by C-peptide levels) was observed in patients di-
agnosed at younger age [21,22]. Lower levels of C-peptide [23] 
and higher glycemic variability [24-26] are known to be associ-
ated with higher risk of diabetic complications. In addition, 
higher glycemic variability in T1DM is associated with the risk 
of microalbuminuria or progression of CKD [27]. In the pres-
ent study, although baseline glycemic control state was compa-
rable between groups, patients diagnosed at younger age were 
prescribed more intensive insulin treatments and higher doses 
of insulin per body weight. In addition, stimulated C-peptide 
levels were significantly lower in the group with younger age at 
onset. These results suggest that patients diagnosed at younger 
age might be vulnerable to the risk of macroalbuminuria ac-
companied by rapid decline in renal function due to the rapid 
decline in β-cell function and consequently higher glycemic 
variability. Thus, age at diagnosis in T1DM can be one of the 
important clinical parameters associated with the risk of DN. 
Previous studies have shown various results on how age at 
diagnosis affects the risk of diabetic complications and cardio-
vascular outcomes according to study design and population. 
A recent Swedish observational cohort study has reported that 
developing T1DM at younger age (<10 years) is associated 
with a higher risk of cardiovascular complications [28]. Har-
jutsalo et al. [29] showed that higher mortality from ischemic 
heart disease was observed in women with early-onset T1DM 
Fig. 2. Relation between disease duration and urine albumin-
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Table 1. Baseline characteristics of young patients with type 1 diabetes mellitus stratified by age at diagnosis
Characteristic Total <20 years of age 20–29 years of age 30–40 years of age P value
Number 255 87 85 83
Age of onset, yr 25 (18–32) 16 (13–18) 26 (23–27) 33 (32–37) <0.001
Age of registration, yr 36 (31–44) 31 (26–36) 37 (31–42) 45 (38–52) <0.001
Disease duration, yr 14 (8–20) 16 (11–22) 13 (7–19) 11 (5–19) 0.001
Male sex 126 (49.4) 37 (42.5) 45 (52.9) 44 (53.0) 0.286
FHx. of diabetes 63 (24.7) 27 (31.0) 18 (21.2) 18 (21.7) 0.418
BMI, kg/m2 22.3 (20.5–24.5) 21.4 (19.4–23.8) 22.9 (20.7–24.6) 22.5 (20.9–24.6) 0.022
SBP, mm Hg 118 (110–128) 115 (107–125) 118 (111–127) 121 (110–135) 0.019
DBP, mm Hg 70 (64–79) 70 (63–78) 71 (64–78) 70 (65–80) 0.609
Total cholesterol, mg/dL 167 (148–190) 164 (149–193) 168 (148–186) 168 (147–195) 0.897
TG, mg/dL 76 (55–105) 73 (53–107) 76 (57–100) 79 (56–111) 0.833
HDL-C, mg/dL 61 (50–75) 60 (49–74) 63 (50–76) 59 (50–73) 0.639
LDL-C, mg/dL 91 (76–109) 93 (77–108) 90 (73–109) 90 (75–109) 0.781
BUN, mg/dL 14.8 (12.0–19.5) 15.0 (11.2–20.1) 16.1 (12.5–21.1) 14.0 (12.0–16.9) 0.172
Creatinine, mg/dL 0.8 (0.7–1.0) 0.8 (0.7–1.1) 0.8 (0.7–1.0) 0.8 (0.7–1.0) 0.858
uACR, mg/g 9.7 (4.7–47.0) 20.7 (4.9–59.4) 7.3 (3.7–14.7) 9.2 (4.8–20.7) 0.002
eGFR, mL/min/1.73 m² 91.8 (80.1–110.7) 90.1 (75.5–114.2) 95.0 (80.0–115.7) 90.3 (82.0–102.4) 0.524
FPG, mg/dL 150 (102–186) 132 (102–190) 131 (100–175) 140 (97–195) 0.704
HbA1c, % 7.9 (7.0–9.0) 7.6 (7.0–8.9) 7.8 (7.0–8.8) 8.2 (7.0–9.1) 0.419
Fasting C-peptide, ng/mL 0.07 (0.02–0.43) 0.02 (0.01–0.16) 0.08 (0.02–0.43) 0.19 (0.02–0.48) 0.094
Stimulated C-peptide, ng/mL 0.10 (0.02–0.60) 0.02 (0.01–0.38) 0.19 (0.02–0.63) 0.27 (0.02–0.68) 0.047
Presence of autoantibodya 87 (51.8) 27 (52.9) 37 (59.7) 23 (41.8) 0.152
   Anti-GAD Ab 82 (94.3) 24 (88.9) 36 (97.3) 22 (95.7)
   Other autoantibodies 5 (5.7) 3 (11.1) 1 (2.7) 1 (4.3)
Intensive insulin treatment 170 (66.7) 71 (81.6) 51 (60.0) 48 (57.8) 0.001
Total daily insulin dose, IU/kg 0.64 (0.52–0.79) 0.7 (0.6–0.9) 0.6 (0.5–0.8) 0.6 (0.5–0.7) 0.001
Medication use
   Oral glucose lowering drugs 60 (23.5) 14 (16.1) 20 (23.5) 26 (31.3) 0.065
   Antihypertensive drugs 67 (26.3) 28 (32.2) 19 (22.4) 20 (24.1) 0.294
   Statins 66 (25.9) 24 (27.6) 19 (22.4) 23 (27.7) 0.661
Smoking 0.008
   Current smoker 31 (12.2) 6 (7.4) 7 (9.6) 18 (24.0)
   Ex-smoker 39 (15.3) 10 (12.3) 16 (21.9) 13 (17.3)
   Non-smoker 159 (62.4) 65 (80.2) 50 (68.5) 44 (58.7)
Diabetic retinopathy 109 (42.7) 52 (61.9) 24 (28.9) 33 (40.2) <0.001
Diabetic nephropathy 43 (16.9) 22 (25.3) 13 (15.3) 8 (9.6) 0.022
Values are presented as median (interquartile range) or number (%). Intensive insulin treatment, multiple daily injection or continuous subcutaneous 
insulin injection; Diabetic retinopathy, the presence of mild non-proliferative retinopathy or more; Diabetic nephropathy, uACR ≥300 mg/g or eGFR 
≤60 mL/min/1.73 m2. 
FHx, family history; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; HDL-C, high-density lipopro-
tein cholesterol; LDL-C, low density lipoprotein cholesterol; BUN, blood urea nitrogen; uACR, urine albumin-creatinine ratio; eGFR, estimated glo-
merular filtration ratio; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; anti-GAD Ab, anti-glutamic acid decarboxylase antibody. 
an=168. 
Age at diagnosis and diabetic nephropathy
51Diabetes Metab J 2021;45:46-54 https://e-dmj.org
(aged <15 years) compared to that in those with late-onset 
(aged 15 to 29 years). With regard to DN, previous studies have 
reported that the age of onset before 10 years is associated with 
lower risk of developing ESRD compared to those who are di-
agnosed at age of 20 to 34 years [30] or at age of 10 to 14 years 
[31]. In our study, age at diagnosis was associated with macro-
albuminuria but not with CKD. Given that the incident rate of 
ESRD starts to rise at 15 years after diagnosis with increase to a 
plateau up to 25 years after diagnosis [32], it might be difficult 
to identify the relationship between age at diagnosis and CKD 
due to the relatively short duration of diabetes (median, 14 
years) and the small number of patients in this study. However, 
the current study revealed that younger age onset group had an 
independent high risk for macroalbuminuria. This might ex-
plain the relationship between age at diagnosis and progression 
to ESRD, cardiovascular complications or the overall mortality. 
As a result, early detection and management of albuminuria 
are important, especially in those diagnosed at childhood/ado-
lescent. 
In our study, even though age at diagnosis was independent-
ly associated with the risk of DN (predominantly associated 
with macroalbuminuria), the presence of DR was not associat-
Table 2. Risk factors associated with diabetic complications
Variable
Diabetic nephropathy Diabetic retinopathy
OR (95% CI) P value OR (95% CI) P value
Male sex 0.94 (0.47–1.88) 0.936 0.53 (0.32–0.86) 0.011
Disease duration, yr 1.08 (1.03–1.12) <0.001 1.11 (1.08–1.14) <0.001
HbA1c, % 1.36 (1.13–1.64) 0.001 1.28 (1.12–1.47) <0.001
SBP, mm Hg 1.02 (0.99–1.04) 0.160 1.02 (1.00–1.04) 0.022
BMI, kg/m2 0.95 (0.86–1.05) 0.319 0.99 (0.91–1.06) 0.708
Intensive insulin treatment 0.96 (0.46–2.01) 0.917 0.85 (0.50–1.44) 0.537
Age at diagnosis groups, yr 0.020 0.916
   <20 3.47 (1.45–8.33) 0.005 1.12 (0.63–1.99) 0.701
   20–29 1.80 (0.77–4.24) 0.177 1.01 (0.57–1.78) 0.975
   30–40 1 (reference) - 1 (reference) -
Intensive insulin treatment, multiple daily injection or continuous subcutaneous insulin injection.
OR, odds ratio; CI, confidence interval; HbA1c, glycosylated hemoglobin; SBP, systolic blood pressure; BMI, body mass index.
Table 3. Risk factors associated with macroalbuminuria or chronic kidney disease
Variable
Macroalbuminuria Chronic kidney disease
OR (95% CI) P value OR (95% CI) P value
Male sex 0.62 (0.27–1.43) 0.264 1.21 (0.53–2.78) 0.651
Disease duration, yr 1.09 (1.04–1.14) <0.001 1.09 (1.04–1.14) <0.001
HbA1c, % 1.46 (1.18–1.79) <0.001 1.25 (1.01–1.55) 0.036
SBP, mm Hg 1.01 (0.98–1.03) 0.652 1.02 (0.99–1.04) 0.195
BMI, kg/m2 0.95 (0.85–1.07) 0.408 0.98 (0.87–1.10) 0.730
Intensive insulin treatment 0.47 (0.20–1.12) 0.090 0.29 (0.09–0.92) 0.036
Age at diagnosis groups, yr
   <20 6.43 (2.30–17.99) <0.001 2.32 (0.78–6.94) 0.131
   20–29 1.47 (0.48–4.51) 0.502 2.85 (0.97–8.32) 0.056
   30–40 1 (reference) - 1 (reference) -
Intensive insulin treatment, multiple daily injection or continuous subcutaneous insulin injection.
OR, odds ratio; CI, confidence interval; HbA1c, glycosylated hemoglobin; SBP, systolic blood pressure; BMI, body mass index.
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ed with age at diagnosis. A retrospective cohort study from 
Spain demonstrated that the rate of incident DR is higher in 
patients who were older at T1DM diagnosis compared with 0 
to 9 years old group (reference group), although it is not signif-
icantly different among subgroups of those aged 10 to 44 years 
old [33]. Kullberg et al. [34] stated that the prevalence of DR 
has a non-linear correlation with age at diagnosis. It was the 
lowest among patients aged <5 years and increased up to 48% 
in those aged 15 to 19 years and then decreased to 30% in pa-
tients aged 30 to 36 years at diagnosis. The effect of age at diag-
nosis on the risk of DR was heterogeneous according to age 
group, especially for the age of 10 to 40 years old. When con-
sidering puberty that is known to be an important accelerator 
for DR [35], young adolescent group after puberty or late-on-
set group (age >45 years old) could be high risk group for DR. 
This study has several limitations. First, results were drawn 
from patients enrolled at only three hospitals. Thus, they could 
not represent all Korean patients with T1DM. Second, the na-
ture of this retrospective study limits the full evaluation of dia-
betic complications, and a number of missing data were ex-
cluded from this study. Moreover, the relationship between age 
at diagnosis and diabetic microvascular complications was not 
conclusive in this cross-sectional study. A large number of pro-
spective studies are needed to determine the causal correlation 
between age-at-diagnosis and the progression in diabetic com-
plications in the future. Third, we limited the age at onset to be 
before 40 years old to include young adult T1DM patients and 
exclude those who had atypical forms of T1DM or long-stand-
ing T2DM. However, the inclusion criteria according to reim-
bursement policy might not be enough to limit to typical 
T1DM patients only. Fourth, only spot albuminuria or eGFR 
was assessed and the progression or improvement of DN with 
follow-up was unavailable in this study. Fifth, time-dependent 
changes in glycemic control and diabetic complications were 
not assessed to evaluate the causal relationship between age at 
diagnosis and complications. Sixth, glycemic variability was 
not assessed directly in this study. A more detailed study using 
methods such as continuous glucose monitoring might enable 
the evaluation of the causal relationship between age at diag-
nosis and diabetic microvascular complications. 
In conclusion, higher albuminuria with progressed renal im-
pairments according to disease duration was observed in 
T1DM patients diagnosed at childhood/adolescent than those 
who were diagnosed at older age. In addition, younger age at 
diagnosis (age <20 years) was independently associated with 
the risk of macroalbuminuria and DN. 
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